Armephaco JSC

Armephaco JSC Debt/EBITDA

The Total Debt to EBITDA Ratio of Armephaco JSC (AMP.VN) as of Nov 1, 2026 is 25.12. In the previous year, Total Debt to EBITDA Ratio was 32.17 — a change of -21.91% (lower).

Debt/EBITDA

25.12

YoY

-21.91%

Last updated:

Total Debt to EBITDA Ratio of Armephaco JSC is 2025 25.12 . Total Debt to EBITDA Ratio of Armephaco JSC was 2024 32.17 . It decreases by -21.91% lower compared to the previous year.

The Armephaco JSC Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
12.63 VND
Jan 1, 2019
9.79 VND
Jan 1, 2020
12.67 VND
Jan 1, 2021
17.82 VND
Jan 1, 2022
20.90 VND
Jan 1, 2023
23.75 VND
Jan 1, 2024
32.17 VND
Jan 1, 2025
25.12 VND
The Armephaco JSC Debt/EBITDA history
YEARDebt/EBITDAYoY
25.12-21.91%
32.17+35.45%
23.75+13.66%
20.90+17.29%
17.82+40.65%
12.67+29.41%
9.79-22.52%
12.63+35.60%
9.32-14.51%
10.90-0.78%
10.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Armephaco JSC Stock analysis

What does Armephaco JSC do? Armephaco JSC manufactures pharmaceutical and medical equipment products, focusing on glucose meters, sphygmomanometers, beds, medical exam tables, stools, and syringe destroyers. The company distributes medical devices and equipment through its manufacturing and distribution channels, targeting healthcare providers and hospitals. It also produces and trades diversified medicines, including antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs, serving the broader healthcare market. The firm generates revenue from the sale of medical devices and equipment, as well as from pharmaceutical products. Healthcare providers and hospitals purchase the medical devices and equipment, while the diversified medicines are sold to pharmacies and healthcare institutions. Armephaco JSC's product portfolio includes glucose meters, sphygmomanometers, beds, medical exam tables, stools, syringe destroyers, antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs. Armephaco JSC's business model centers on the production and distribution of medical devices and pharmaceuticals. The company's primary customers are healthcare providers, hospitals, pharmacies, and healthcare institutions. The revenue streams are derived from the direct sale of medical equipment and pharmaceutical products to these segments, with no mention of additional services or partnerships. Armephaco JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Armephaco JSC stock

Total Debt to EBITDA Ratio of Armephaco JSC is 25.12 in 2025.

Total Debt to EBITDA Ratio of Armephaco JSC changed from 32.17 to 25.12, representing a -21.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Armephaco JSC since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Armephaco JSC with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Armephaco JSC

All Key Metrics — Armephaco JSC